|
5th International AIDS Society Conference on HIV Pathogenesis and TreatmentCape Town - July 19 - 22, 2009 |
SURVIVAL RATES FOLLOWING EXPANSION OF THE NATIONAL PEDIATRIC ANTIRETROVIRAL TREATMENT PROGRAM, THAILAND, 2000-2005
IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: Abstract No. MOAB101
M. McConnell1, P. Yuktanont2, U. Siangphoe1, N. Pattarapayoon2, S. Kohreanudom2, R. Lolekha1, P.A. Mock1, S. Chasombat2, S. Thanprasertsuk3
1Thailand MOPH - U.S. CDC Collaboration, Nonthaburi, Thailand, 2Department of Disease Control, MOPH, Nonthaburi, Thailand, 3World Health Organization, Bangkok, Thailand
BACKGROUND: There are approximately 16,000 HIV-infected children in Thailand. The Thai government began a national antiretroviral treatment (ART) program in 2000; we describe patient outcomes for HIV-infected children initiating ART between 2000 and 2005.
METHODS: Analysis included all ART-naïve patients < 15 years old who initiated ART from January 2000 - December 2005; patient follow-up data were included through March 2007. ART-eligible children were <1 year old or had CD4% <20 or CDC clinical stage B or C. Lost to follow-up (LFU) patients were >3 months late for a visit or coded by the provider as LFU; LFU patients were cross-checked against the national death registry.
RESULTS: The analysis included 3,409 children who initiated ART at 327 hospitals; 20.2% initiated ART at district/community hospitals and 79.8% at provincial or larger hospitals. Median follow-up time was 1.7 years (IQR = 1.0-2.5). Median age at ART initiation was 7.3 years (IQR = 4.9-9.4), weight-for-age z-score (WAZ) was -2.0 (IQR = -2.6 to -1.4), and CD4% was 5.0% (IQR = 1.9%-13.0%). Baseline ART regimens were nevirapine-based for 2,528 (74.2%) children and efavirenz-based for 698 (20.5%). At the last visit, 346 (10.1%) children were LFU and 305 (9.0%) had died. Of the deaths, 274 (90.1%) were AIDS deaths; median time to death from ART initiation was 3.6 months (IQR = 1.4-10.7). In Kaplan-Meier analysis, the one-year survival probability was 0.93 (95%CI, 0.93-0.94); 5-year survival probability was 0.88 (95%CI, 0.86-0.90). Higher baseline WAZ and CD4% and better clinical stage were associated with survival in the adjusted Cox model (p< 0.001), as was district/community hospital (p< 0.05).
CONCLUSIONS: National expansion of the pediatric ART program in Thailand demonstrates good survival rates, including at district/community hospitals. Poorer outcomes were associated with advanced disease at baseline; efforts to promote early initiation of ART for eligible children should be strengthened.
Download PDF of this abstract.
Download Power Point Presentation.
2009-07-22
MOAB101
Oral Abstract Session MOAB1 - Paediatric ART: Successes and Challenges
Copyright © 2009 - International AIDS Society (IAS). All information and content relating to the abstracts from the 5th International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.